文献速递类风湿关节炎

类风湿关节炎诊疗路径队列与常规诊疗的临床结局比较

Clinical Outcomes of Patients Within the Rheumatoid Arthritis Care Pathway Cohort at a Tertiary Care Integrated Delivery Network: A Comparison to Usual Care.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2025-12-16

本研究在Allegheny健康网络比较类风湿关节炎诊疗路径队列(817例)与常规诊疗队列(3651例)的临床结局。诊疗路径组在6、12、24个月达到CDAI缓解的比例显著更高(24个月时33.5% vs 20.3%;HR 1.53,95%CI 1.11-2.10;P=0.008),平均缓解时间早64天。诊疗路径组RA相关人均月费用显著更高,主要与基线CDAI较高、合并症及生物制剂/靶向合成DMARD使用和转换相关。

要点

  • 诊疗路径组24个月CDAI缓解率33.5% vs 常规诊疗组20.3%(HR 1.53,95%CI 1.11-2.10;P=0.008)。
  • 诊疗路径组平均缓解时间比常规诊疗组早64天。
  • 诊疗路径组RA相关人均月费用显著更高,与基线CDAI、合并症及生物制剂/靶向合成DMARD使用和转换相关。

核心结论

  • 本RA诊疗路径患者比常规诊疗患者更可能达到缓解。
  • RA相关人均月费用相比常规诊疗更高。
  • 作者计划用更长随访研究改善的临床结局是否带来直接和间接费用降低,研究个体化团队诊疗干预的影响,并在其他人群中验证这些发现。

研究设计与样本

  • 比较Allegheny健康网络RA诊疗路径队列与常规诊疗队列的临床结局。
  • 诊疗路径举措在指南推荐的最佳实践基础上实施多学科团队诊疗。
  • 提取临床和保险理赔数据,比较基于CDAI的缓解比例并评估医疗资源利用和人均月费用。
  • RA诊疗路径队列817例,常规诊疗队列3651例。

主要发现

  • 诊疗路径组在6、12、24个月达到缓解的比例显著更高(24个月时33.5% vs 20.3%;HR 1.53,95%CI 1.11-2.10;P=0.008)。
  • 诊疗路径组平均缓解时间比常规诊疗组早64天。
  • 将低疾病活动度患者与缓解患者合并分析时以及在新诊断RA亚组分析中,也观察到这一趋势。
  • 诊疗路径组RA相关人均月费用显著更高,主要与基线CDAI较高、合并症及生物制剂/靶向合成DMARD使用和转换相关。

局限性

  • 作者计划用更长随访研究改善的临床结局是否带来直接和间接费用降低。
  • 作者计划研究个体化团队诊疗干预的影响。
  • 作者计划在其他人群中验证这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We aimed to compare clinical outcomes between patients in the Allegheny Health Network rheumatoid arthritis (RA) care pathway and patients receiving usual care. METHODS: The care pathway initiative implements guideline-based best practice alongside multidisciplinary team-based care. Clinical and insurance claims data were extracted to compare the proportion of patients in clinical disease activity index (CDAI)-based remission and evaluate health care utilization and per-member per-month (PMPM) costs of care. RESULTS: The RA care pathway cohort included 817 patients, and the usual care cohort included 3,651 patients. The care pathway cohort had a significantly higher proportion of patients achieving remission at 6, 12, and 24 months (33.5% vs 20.3%; hazard ratio 1.53, 95% confidence interval 1.11-2.10; P = 0.008 at 24 months), and on average, remission occurred 64 days earlier than usual care. This trend was also observed when including patients with low disease activity with those in remission and in a subgroup analysis of newly diagnosed RA. RA-related PMPM costs were significantly higher in the care pathway group and primarily related to higher baseline CDAI, comorbidities, and biologic/targeted synthetic disease modifying antirheumatic drug use and switching. CONCLUSION: Patients in our RA care pathway were more likely to achieve remission than those in usual care. PMPM RA costs were higher compared to usual care. We plan to use a longer follow-up to investigate if improved clinical outcomes result in reduced direct and indirect costs, to study the impact of individual team-based care interventions, and to validate our findings in other populations.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Sharma T, Barrett TS, Dwyer T, et al. Clinical Outcomes of Patients Within the Rheumatoid Arthritis Care Pathway Cohort at a Tertiary Care Integrated Delivery Network: A Comparison to Usual Care. Arthritis Care Res (Hoboken). 2025. PMID: 40955717. doi:10.1002/acr.25649

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。